FDA approves Vivitrol to treat opioid-dependent patients | Healthcare IT Blogs
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange

FDA approves Vivitrol to treat opioid-dependent patients

Healthcare Blogs - Healthcare IT Blogs
The U.S. Food and Drug Administration today approved Vivitrol to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.

Vivitrol is an extended-release formulation of naltrexone administered by intramuscular injection once a month. Naltrexone works to block opioid receptors in the brain. It blocks the effects of drugs like morphine, heroin, and other opioids. It was approved to treat alcohol dependence in 2006.

You can read more here.

Trouble viewing the contents? Visit MedicineandTechnology.com

Become a fan of MedicineandTechnology on Facebook.


Read More: http://feedproxy.google.com/~r/mdjosephkim/~3/NCHPRqQYtWA/fda-approves-vivitrol-to-treat-opioid.html